Measles-Rubella (MR) Vaccine

The MR vaccine protects against Measles and Rubella. India switched from the MMR (Measles, Mumps, Rubella) in the government programme to MR in 2017 following a national campaign that vaccinated 406 million children. Measles is a leading cause of child death worldwide; Rubella causes congenital rubella syndrome in newborns.

The Measles-Rubella (MR) Vaccine is recommended for 9 months and 15-18 months. It falls under the Childhood vaccine category. Consult your doctor to confirm if this vaccine is right for you based on your health history and existing immunity.

The Measles-Rubella (MR) Vaccine has an efficacy of Measles: 97% after 2 doses; Rubella: 97% after single dose. This means it provides significant protection against Measles (Rubeola) and Rubella (German Measles). Efficacy may vary based on age, health status, and the specific strain encountered.

Common side effects include: Mild fever 7-12 days after vaccination; rash (5-15% of recipients); temporary joint pain (especially in post-pubertal girls from rubella component); febrile seizures (rare. These are typically mild and resolve within 1–3 days. Serious allergic reactions are rare — if you experience difficulty breathing, hives, or rapid heartbeat after vaccination, seek emergency care immediately.

The Measles-Rubella (MR) Vaccine should be avoided by: Severe immunosuppression (HIV with CD4<200); pregnancy; severe allergy to neomycin or gelatin. Always inform your healthcare provider of your full medical history before vaccination.

The Measles-Rubella (MR) Vaccine typically costs Free (UIP) / ₹300–₹500 (private) in India. Government health centres may offer it free or at subsidised prices for eligible age groups. Private hospitals and clinics may charge differently. Additional fees may apply for administration.